Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer

Clin Breast Cancer. 2009 Nov;9(4):E1-3. doi: 10.3816/CBC.2009.n.046.

Abstract

Resistance to chemotherapy is a complex and very frequent problem in the treatment of breast cancer. It is associated with a poor prognosis and short overall survival. We report a patient with advanced breast cancer without response to anthracyclines or taxanes but who controlled the disease for 15 months with the combination of ixabepilone and capecitabine.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anthracyclines / administration & dosage
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Breast Neoplasms / drug therapy*
  • Bridged-Ring Compounds / administration & dosage
  • Capecitabine
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Disease-Free Survival
  • Drug Resistance, Neoplasm*
  • Epothilones / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / analogs & derivatives
  • Humans
  • Taxoids / administration & dosage
  • Treatment Outcome

Substances

  • Anthracyclines
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Bridged-Ring Compounds
  • Epothilones
  • Taxoids
  • Deoxycytidine
  • taxane
  • Capecitabine
  • ixabepilone
  • Fluorouracil